Immunocore Holdings plc
IMCR
$33.50
$1.916.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.78% | 25.75% | 24.37% | 24.32% | 26.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.78% | 25.75% | 24.37% | 24.32% | 26.54% |
| Cost of Revenue | -122.26% | -65.56% | -487.69% | -101.13% | -108.59% |
| Gross Profit | 30.45% | 29.24% | 48.08% | 219.01% | 219.79% |
| SG&A Expenses | 3.88% | 3.62% | 7.81% | -6.21% | 7.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,112.37% | -2,112.37% | -2,112.37% | 12,914.29% | 12,914.29% |
| Total Operating Expenses | 8.16% | 7.55% | 16.98% | 17.14% | 29.72% |
| Operating Income | 61.94% | 59.17% | 13.44% | 6.15% | -43.28% |
| Income Before Tax | 62.22% | 65.40% | 13.06% | -5.94% | -29.63% |
| Income Tax Expenses | 52.25% | 79.31% | 66.98% | -137.17% | -125.31% |
| Earnings from Continuing Operations | 62.99% | 64.12% | 7.60% | 31.62% | 12.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.99% | 64.12% | 7.60% | 31.62% | 12.02% |
| EBIT | 61.94% | 59.17% | 13.44% | 6.15% | -43.28% |
| EBITDA | 65.16% | 62.62% | 14.61% | 6.07% | -49.94% |
| EPS Basic | 63.26% | 64.53% | 9.74% | 33.70% | 14.51% |
| Normalized Basic EPS | 59.78% | 63.37% | 21.13% | -6.44% | -31.16% |
| EPS Diluted | 62.84% | 64.15% | 9.37% | 33.33% | 15.42% |
| Normalized Diluted EPS | 59.25% | 62.89% | 20.71% | -6.92% | -29.78% |
| Average Basic Shares Outstanding | 0.95% | 1.49% | 2.26% | 2.79% | 3.47% |
| Average Diluted Shares Outstanding | 0.74% | 1.26% | 1.08% | 1.59% | 3.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |